Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress.

By T. Lammers, Fabian Kiessling, W. E. Hennink, G. Storm. Journal of Controlled Release, 2012

1,266 citations recorded by the source corpus.

Subfields: Biomaterials, Biomedical Engineering, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/505d21fd32062dbcea8d636f8feb9a8b7bb7e1eb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Biomedical Engineering

In Molecular Biology

Citations in the corpus

Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. (2014, background): “Similarly, because molecular targets are usually situated in the extravascular space of the tumor, NPs rely on the EPR effect to reach their targets [113, 114].”
Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization (2018, background): “Currently, it is recognized that EPR is a very heterogeneous phenomenon as it depends on the type of tumor and can vary significantly within the same tumor type (Lammers et al., 2012; Ojha et al., 2017).”
Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target? (2013, background): “The aggregate EPR effect is dependent on factors, (15, 16) in which tumor-specific biological features are considered to affect the heterogeneity, including 1.”
Basics and recent advances in peptide and protein drug delivery (2013, critical): “The EPR effect may also be overstated; thus passive targeting of NPs is not as good as once thought [195].”
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. (2013, background): “If such setups are available, the combination of extravasation-enhancing pretreatment with nanomedicine treatment can lead to significant increases in therapeutic efficacy [74].”
Current trends in the use of liposomes for tumor targeting (2013, background): “Targeting of these drugs relies solely on the pathophysiological properties of the tumor tissues, and is referred to as `passive drug targeting' [8,13,14].”
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. (2017, background): “The practicalities of evaluating the EPR effect in human tumours are relatively costly and time-consuming [15,50,55].”
Biodistribution and Delivery Efficiency of Unmodified Tumor-Derived Exosomes (2014, background): “The rapid clearance of liposomes by the reticuloendothelial system (RES), overestimation of the enhanced permeation and retention (EPR) effect, and minimal cell penetration after extravasation from blood vessels by both passively and actively targeted liposomes, have prevented liposomes from becomin”